By David Bautz, PhD
NASDAQ: BDRX
READ THE FULL BDRX RESEARCH REPORT
We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on developing differentiated therapies for rare and difficult-to-treat cancers. The company’s strategy centers on advancing scientifically validated mechanisms with the potential to address clear unmet medical needs, particularly in settings where existing therapies provide only transient benefit or have permanent life-altering impact on quality of life. Biodexa’s pipeline is anchored by two core assets: MTX240, a novel molecular glue therapy targeting the PDE3A–SLFN12 axis with potential applications in gastrointestinal stromal tumors (GIST) and other malignancies, and MTX230 (eRAPA), a reformulated version of the mTOR inhibitor rapamycin that is currently in a registrational Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
We believe Biodexa represents a compelling deep value opportunity, with its current valuation failing to fully reflect the scientific rationale and clinical potential of its lead programs. While MTX230 provides a late-stage, de-risked asset with a clear regulatory pathway, MTX240 introduces a first-in-class mechanism that could offer meaningful differentiation in the treatment of GIST. Together, these programs create a balanced pipeline with both near-term catalysts and longer-term value inflection points.
MTX240 Offers a Differentiated MOA for GIST
MTX240 is designed to exploit a novel tumor-selective cell death pathway involving PDE3A and SLFN12 that operates independently of traditional kinase signaling. This molecular glue mechanism enables selective induction of apoptosis only in cancer cells expressing both targets, offering a differentiated approach to treating tumors that have developed resistance to standard therapies. If validated clinically, MTX240 could establish a new therapeutic class for the treatment of GIST.
Significant Unmet Need in GIST Supports Opportunity for Novel Therapies
Despite multiple approved tyrosine kinase inhibitors, most patients with GIST ultimately develop resistance, resulting in limited durability of response across later lines of therapy. Current treatments primarily target KIT and PDGFRA mutations, but the heterogeneity of resistance mechanism creates an opportunity for therapies with alternative modes of action. MTX240’s kinase-independent mechanism positions it as a potentially valuable option in this treatment landscape.
MTX230 (eRAPA) Provides Late-Stage Exposure to a High-Value Orphan Indication
MTX230 is being evaluated in a registrational Phase 3 trial for familial adenomatous polyposis, a rare genetic condition with a near-certain progression to colorectal cancer if left untreated. Current management relies heavily on prophylactic surgery, underscoring the need for effective pharmacologic interventions. By targeting mTOR signaling downstream of APC mutations, eRAPA has the potential to modify disease progression and delay, and maybe even prevent the need for life-altering surgery.
Valuation
We value Biodexa using a probability-adjusted discounted cash flow model that takes into account potential future revenues for MTX240 and MTX230. While not currently a part of the model, MTX228 may offer additional upside to our valuation in the future.
MTX240: In the U.S., we assume a treatable population of approximately 5,000 patients, with MTX240 achieving close to 55% peak market share in later-line settings. At an annual price of $200,000, this yields peak revenues in the U.S. of approximately $600 million. In Europe, we estimate a treatable population of approximately 11,000 patients. Applying a 45% peak market share and a yearly price of $150,000, we derive peak E.U. revenue of approximately $550 million. Combined, these assumptions result in total peak global revenue for MTX240 of approximately $1.15 billion, which would position MTX240 as a potential blockbuster asset. We model for MTX240 to launch in 2032 with a 7-year ramp to peak sales and for the company to receive a 12% royalty on net sales from a commercialization partner. We apply a 15% discount rate and a 20% probability of approval, which yields an NPV of $27 million.
While derived from a traditional DCF model, recent transactions and market precedents in GIST and rare oncology provide important context for potential upside:
- The approximately $1 billion acquisition of IDRx by GlaxoSmithKline underscores the strategic value of differentiated GIST assets, even at relatively early stages of development. Notably, IDRx’s program is focused on next-generation KIT inhibitors, whereas MTX240 represents a mechanistically different approach targeting the PDE3A-SLFN12 axis and potentially overcoming kinase resistance.
- Cogent Biosciences experienced an approximately $2 billion increase in market capitalization following the release of positive data from the Phase 3 PEAK trial for imatinib-resistant GIST, thus showing the sensitivity of valuations for GIST companies on clinical efficacy. This outcome suggests that even early positive signals for MTX240 could drive disproportionate valuation inflection relative to its current implied value.
MTX230: In the U.S., we assume a treatable FAP population of approximately 33,000 patients. Applying a 27% peak market share and annual pricing of $150,000, we derive peak U.S. revenue of approximately $1.5 billion. In the E.U., we estimate a treatable population of approximately 25,000 patients, with 22% peak market penetration and pricing of $75,000 annually, resulting in peak E.U. revenue of approximately $460 million. Combined, these assumptions yield total peak revenue of almost $2 billion, positioning MTX230 as a multi-billion-dollar commercial opportunity within a rare disease setting due to the combination of chronic treatment, high unmet need, and favorable orphan drug pricing. We model for MTX230 to launch in 2031 with a 7-year ramp to peak sales and for the company to receive a 12% royalty on net sales from a commercialization partner. We apply a 15% discount rate and a 50% probability of approval, which yields an NPV of $126 million.
Similarly to MTX240, while this valuation is derived from a DCF model, the following external benchmarks in rare disease and mTOR-targeted therapies provide important context:
- The current approximately $1.4 billion market cap of Palvella Therapeutics, driven by a Phase 3 topical rapamycin program in microcystic lymphatic malformations, a disease with comparable incidence to FAP, highlights the premium valuation investors assign to late-stage rare disease assets with validated biology. Notably, MTX230 targets a broader systemic indication with a larger commercial opportunity, suggesting that its valuation could ultimately converge toward similar levels with positive Phase 3 results.
- An additional benchmark can be seen in the sale of Fyarro (an mTOR inhibitor) for approximately $100 million in an ultra-rare oncology indication (PEComa), which further supports the strategic value of rapamycin-based therapeutics, even in small patient populations. MTX230 benefits from a similar mechanism of action but is positioned in a chronic, preventative setting with significantly greater revenue potential.
Combining the NPVs for MTX240 and MTX230 with the current cash position ($5 million) and the potential cash from warrant exercises (approximately $34 million) leads to a net present value for Biodexa of $193 million. The company currently has 3.7 million ADSs and approximately 6.3 million warrants outstanding for a fully diluted ADS count of approximately 10 million. We add an additional 17 million ADSs to account for future dilution, which leads to a valuation of $7 per ADS.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.